Biomunex to Present Preclinical Data on MAIT Engager Platform at 2025 SITC Annual Meeting Biomunex Pharmaceuticals, an innovative French biopharmaceutical company advancing the next generation of antibody-based immunotherapies, announced that it will present new preclinical data from its proprietary MAIT…
Mirum Pharmaceuticals Announces Third Quarter 2025 Results and Highlights Strong Commercial Execution, Pipeline Advancement, and Strategic Positioning for 2026–2027 Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company dedicated to transforming the treatment landscape for rare liver diseases, announced its financial…
PharmaJet to Showcase Advancements in Intradermal Needle-Free Delivery at ASTMH Annual Meeting PharmaJet®, a leading company focused on transforming injectable delivery through needle-free technology, announced that it will present new results and strategic insights from its intradermal (ID) programs at…
Vertex Pharmaceuticals Reports Robust Third Quarter 2025 Results and Refines Full-Year Outlook as Pipeline Momentum Accelerates Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX), a global leader in genetic and transformative medicine, today announced financial results for the third quarter ended September 30,…
PureTech’s Gallop Oncology to Present Promising Phase 1b Data of LYT-200 in Relapsed/Refractory AML at the 2025 ASH Annual Meeting PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a biotherapeutics innovator renowned for its hub-and-spoke model that…
Auna S.A. Reports Early Results of Cash Tender Offer and Consent Solicitation for 10.000% Senior Secured Notes Due 2029 Auna S.A. (NYSE: AUNA), a Luxembourg-based public limited liability company and one of Latin America’s leading integrated healthcare providers, announced the…
Agenus Reports Durable Two-Year Survival with BOT/BAL Combination Across Refractory Solid Tumors at ESMO 2025 Agenus Inc. (Nasdaq: AGEN), a biotechnology company recognized for its pioneering work in immuno-oncology, unveiled highly encouraging new clinical data from its novel combination therapy…
Sanofi and EVOQ Therapeutics Form $500 Million Partnership to Advance Autoimmune Therapies Sanofi, a global pharmaceutical giant, has entered into a strategic collaboration with EVOQ Therapeutics, a clinical-stage biotechnology company, to jointly develop and commercialize novel therapies targeting autoimmune diseases.…
FDA’s Orphan Drug Leadership Shifts Amid Policy Changes and Department-Wide Shakeups Sandra Retzky, formerly the top orphan drug regulator at the FDA, is no longer serving as director of the Office of Orphan Products Development. The departure, first reported by…
Roche Showcases Breakthrough Sequencing by Expansion (SBX) Technology and Sets New GUINNESS WORLD RECORD™ at ASHG 2025 Roche (SIX: RO, ROG; OTCQX: RHHBY) unveiled a series of groundbreaking advancements in its Sequencing by Expansion (SBX) technology during the American Society…
Adagio Medical Announces Up to $50 Million Private Placement to Advance Cardiac Arrhythmia Therapies Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or the “Company”), a leading innovator in the development of catheter ablation technologies for the treatment of cardiac arrhythmias,…
Transforming Autoimmune and Inflammatory Disease Therapies WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), proudly congratulates Dr. Fred Ramsdell, PhD, co-founder and Chair of the Scientific Advisory Board of its client Sonoma Biotherapeutics, on being…
